Why Participate?
Goal is to Improve Care
There are more than 2.3 million people in the United States living with inflammatory bowel disease, which includes both Crohn’s disease and ulcerative colitis. We still have a lot to learn about possible treatments.
There are limited Food and Drug Administration (FDA) approved medications for use in children and adults with Crohn’s disease. We are looking for new and possibly better treatment options. Research studies can aid in this search.
Our team is looking for new methods to deliver the current medications to keep patients healthier longer.
Although we can’t promise a direct benefit, possible benefits include improved control of your Crohn’s disease and improved drug durability (longer time on the drug).
This study will provide invaluable data regarding future treatment plans for dosing infliximab.
About Research
Participation in research is completely voluntary.
Prior to participating in this research, you will have an opportunity to review all of the details of the study along with potential benefits and risks associated with the clinical trial.
You or your guardian will need to sign a consent form before participation.